South Korea news brief
South Korea's Celltrion signs $580.5M drug licensing deal
🇰🇷 South KoreaNEWS DESKPublisher image not supplied
NEWS DESKSouth Korea
PUBLISHEDOct 22, 2026, 2:21 PM
What the source reports
Celltrion signed a drug licensing deal worth up to $580.5 million with U.S. biotech Kaigene, securing a third autoimmune treatment candidate.
Main source: Bing News – South Korea
TDBN presents the written preview supplied through the publisher's feed. Complete reporting, continuing updates, context, and corrections remain with the original report.
Read the complete report ↗